Wal-Mart de Mexico Proposes Ignacio Caride as Next CEO
By Anthony Harrup
Wal-Mart de Mexico, Mexico's biggest retailer by sales, will propose Ignacio Caride as its new chief executive as the current CEO takes on another role at Walmart International.
Walmex, as the unit of Bentonville, Ark.-based Walmart is known, said Friday that Caride would replace Guilherme Loureiro, who will be appointed Walmart's regional director for Canada, Chile, Mexico and Central America.
Caride joined Walmex from MercadoLibre.com in 2018 as vice president of ecommerce, and last year took charge of the company's omnichannel operations. He designed the strategy for the retailer's financial services, including credit and remittances, Walmex said.
His appointment as CEO will be proposed at the company's board meeting on April 30. The two executives will begin a transition period over the next two months, Walmex said.
The company added that Loureiro is expected to be appointed chairman of the Walmex board in the second half of this year.
Write to Anthony Harrup at anthony.harrup@wsj.com
(END) Dow Jones Newswires
April 12, 2024 12:03 ET (16:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track